“Inceptive is the first biological software company,” declared Jakob Uszkoreit, co-founder and CEO of the AI-driven biotech startup, during a recent interview. This bold vision aims to transform medicine by harnessing the power of generative AI to design novel therapeutic molecules.
Uszkoreit, who co-authored the seminal 2017 paper introducing transformers while at Google, sees immense potential in applying AI to drug discovery. He explained: “We use generative AI to design RNA molecules that later form the core of what we see as a next generation of medicines.”
The promise of this approach lies in creating treatments that work in harmony with biological systems.
“There’s actually this promise of a flavor of medicine that is in much greater harmony with living systems than most existing medicines,” Uszkoreit elaborated.
Drawing parallels to recent breakthroughs, he noted: “One thing that was special about the mRNA Covid vaccines is that they effectively instructed our cells to produce a protein in a way that really is exactly mimicking the way ourselves constantly produce protein to keep us alive.”
Inceptive aims to take this concept further, developing “medicines with capabilities that are far away, more advanced than what we can do today.” Uszkoreit envisions drugs that can “exhibit certain behaviors only in certain conditions, identify whether or not the medicine has entered a diseased cell or one that’s actually healthy, and if they have entered one that’s healthy, they might just decide to disintegrate.”
While some may worry about potential risks of AI, Uszkoreit remains optimistic about its transformative potential in healthcare.
“There’s so much positive potential, so much potential to address some of the biggest challenges we are facing as a species — climate change, the next, the next disease outbreak, the next pandemic,” he said.
He argued that responsible development is key: “The best way of limiting that danger is really to push the development of this technology in responsible ways forward, as fast as we can.”
For those looking to enter the field, Uszkoreit recommended a multidisciplinary approach: “A really combination of natural sciences, healthy dose of math and, you know, good helping of computer science.”
As AI continues to reshape industries, Uszkoreit’s work at Inceptive stands at the forefront of a revolution in drug development, promising to unlock new possibilities in treating disease and improving human health.
Featured image: Credit: Inceptive
